Advertisement

The Discovery of the Hepatitis C Virus

  • Michael HoughtonEmail author
Chapter
Part of the Topics in Medicinal Chemistry book series (TMC, volume 31)

Abstract

After a 6-year intensive search for the causative agent of parenteral non-A, non-B hepatitis using a large variety of pre-PCR molecular biological, immunological, and virological methods, HCV was discovered using a cDNA immunoscreening method in which infectious chimpanzee plasma was used as the source of cloning material and NANBH patient sera as a presumptive source of NANBH-specific antibodies. Clone 5-1-1 and overlapping clones were shown to be extrachromosomal in origin, to be derived from a large single-stranded RNA found only in NANBH materials and which directly encoded an antigen shown to specifically bind antibodies in most parenteral NANBH-infected chimpanzees and patients. The nucleotide sequence of the RNA genome exhibited low homology with flaviviruses which in combination proved that HCV was the major cause of blood-borne NANBH and that it was a distant relative of the Flaviviridae family. Since 1990, a series of HCV-specific antibody- and RNA-detecting blood screening tests have effectively eliminated posttransfusion HCV infections. Subsequent decades of research by the field into the viral life cycle and the development of direct-acting antivirals have now led to HCV becoming the first curable, chronically infecting virus of man. It is now important to focus on a prophylactic vaccine to curtail this global epidemic.

Keywords

Blood-borne NANBH Flaviviridae HCV HCV blood tests HCV discovery HCV identification Hepatitis C virus Non-A, non-B hepatitis 

Notes

Compliance with Ethical Standards

Funding This study was funded by the Canada Excellence in Research Chairs program, Alberta Innovates and the Li Ka Shing Institute of Virology.

Conflict of Interest

Author is a director and stock holder of Aurora Vaccines Inc.

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Houghton M (2000) Identification of the hepatitis C virus. Nat Med 6(10):1084–1086Google Scholar
  2. 2.
    Houghton M (2009) Discovery of the hepatitis C virus. Liver Int 29(Suppl 1):82–88CrossRefGoogle Scholar
  3. 3.
    Houghton M (2009) The long and winding road leading to the identification of the hepatitis C virus. J Hepatol 51(5):939–948CrossRefGoogle Scholar
  4. 4.
    Houghton M (2016) Towards the control of hepatitis C. In: Miyamura T, Lemon S, Walker C, Wakita T (eds) Hepatitis C virus I. Springer, TokyoGoogle Scholar
  5. 5.
    Prince AM, Brotman B, Grady GF, Kuhns WJ, Hazzi C, Levine RW, Millian SJ (1974) Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 2(7875):241–246CrossRefGoogle Scholar
  6. 6.
    Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV (1975) Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 292(15):767–770CrossRefGoogle Scholar
  7. 7.
    Bayer ME, Blumberg BS, Werner B (1968) Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s Syndrome and hepatitis. Nature 218:1057–1059CrossRefGoogle Scholar
  8. 8.
    Feinstone SM, Kapikian AZ, Purcell RH (1973) Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182:1026–1028CrossRefGoogle Scholar
  9. 9.
    Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220(4599):868–871CrossRefGoogle Scholar
  10. 10.
    Hollinger FB, Mosley JW, Szmuness W, Aach RD, Peters RL, Stevens C (1980) Transfusion-transmitted viruses study: experimental evidence for two non-A, non-B, hepatitis agents. J Infect Dis 142(3):400–407CrossRefGoogle Scholar
  11. 11.
    Alter HJ (1980) The dominant role of non-A, non-B in the pathogenesis of post-transfusion hepatitis: a clinical assessment. Clin Gastroenterol 9(1):155–170 ReviewPubMedGoogle Scholar
  12. 12.
    Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F, Frösner G, Matanoski GM (1982) Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 145(6):886–893CrossRefGoogle Scholar
  13. 13.
    Bradley DW, Cook EH, Maynard JE, McCaustland KA, Ebert JW, Dolana GH, Petzel RA, Kantor RJ, Heilbrunn A, Fields HA, Murphy BL (1979) Experimental infection of chimpanzees with antihemophilic (factor VIII) materials: recovery of virus-like particles associated with non-A, non-B hepatitis. J Med Virol 3(4):253–269CrossRefGoogle Scholar
  14. 14.
    Bradley DW, Maynard JE, Popper H, Cook EH, Ebert JW, McCaustland KA, Schable CA, Fields HA (1983) Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents. J Infect Dis 148(2):254–265CrossRefGoogle Scholar
  15. 15.
    Shimizu YK, Feinstone SM, Purcell RH, Alter HJ, London WT (1979) Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science 205:197–200CrossRefGoogle Scholar
  16. 16.
    Bradley DW, McCaustland KA, Cook EH, Schable CA, Ebert JW, Maynard JE (1985) Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 88(3):773–779CrossRefGoogle Scholar
  17. 17.
    He LF, Alling D, Popkin T, Shapiro M, Alter HJ, Purcell RH (1987) Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 156(4):636–640CrossRefGoogle Scholar
  18. 18.
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11(7):791–796. Epub 2005 Jun 12. Erratum in: Nat Med. 2005 Aug;11(8):905CrossRefGoogle Scholar
  19. 19.
    Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, Mullenbach GT, Denniston KJ, Gerin JL, Houghton M (1986) Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature 323(6088):508–514 Erratum in: Nature 1987 Jul 30–Aug 5;328(6129):456CrossRefGoogle Scholar
  20. 20.
    Weiner AJ, Wang KS, Choo QL, Gerin JL, Bradley DW, Houghton M (1987) Hepatitis delta (delta) cDNA clones: undetectable hybridization to nucleic acids from infectious non-A, non-B hepatitis materials and hepatitis B DNA. J Med Virol 21(3):239–247CrossRefGoogle Scholar
  21. 21.
    Shimizu YK, Oomura M, Abe K, Uno M, Yamada E, Ono Y, Shikata T (1985) Production of antibody associated with non-A, non-B hepatitis in a chimpanzee lymphoblastoid cell line established by in vitro transformation with Epstein-Barr virus. Proc Natl Acad Sci U S A 82(7):2138–2142CrossRefGoogle Scholar
  22. 22.
    Feinstone SM, Alter HJ, Dienes HP, Shimizu Y, Popper H, Blackmore D, Sly D, London WT, Purcell RH (1981) Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 144(6):588–598CrossRefGoogle Scholar
  23. 23.
    Prince AM (1985) Reliability of chimpanzee model for non-A, non-B hepatitis. Lancet 2(8464):1134CrossRefGoogle Scholar
  24. 24.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902):359–362CrossRefGoogle Scholar
  25. 25.
    Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE et al (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244(4902):362–364CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG  2019

Authors and Affiliations

  1. 1.Li Ka Shing Institute of Virology, Department of Medical Microbiology and ImmunologyUniversity of AlbertaEdmontonCanada

Personalised recommendations